|
|
|
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer |
|
|
| May
30, 2007--The
US FDA has approved Wyeth Pharmaceuticals’ TORISEL (temsirolimus)
for patients with advanced renal cell carcinoma. TORISEL
is the first targeted renal cancer therapy proven to
extend median overall survival versus interferon-alpha, an
active comparator, in this patient population. TORISEL is
the only marketed cancer therapy that specifically
inhibits the mTOR kinase, a key protein in cells that
regulates cell proliferation, cell growth, and cell
survival. Wyeth |
|
|
|
|
|
|
